Use of peptide epoxyketones for metastasis suppression

• US 8,853,147 B2
• Filed: 11/11/2010
• Issued: 10/07/2014
• Est. Priority Date: 11/13/2009
• Status: Active Grant

• Current Assignee: Onyx Therapeutics, Inc. (Amgen Inc.)
• Original Assignee: Onyx Therapeutics, Inc. (Amgen Inc.)
• Inventors: Kirk, Christopher J., Jiang, Jing
• Primary Examiner(s): Garcia, Marcela M Cordero
• Assistant Examiner(s): YANG, KAIPEEN E
• Application Number:
  US13/509,226
• Publication Number:
  US 20130035295A1
• Time in Patent Office: 1,426 Days
• US Class Current: 514/1.1
• CPC Class Codes: A61K 31/336 having three-membered rings, e.g. oxirane, fumagillin
• CPC Class Codes: A61K 38/05 Dipeptides
• CPC Class Codes: A61K 38/06 Tripeptides
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: C07K 5/081 the side chain containing O or S as heteroatoms, e.g. Cys, Ser

Abstract

The invention provides a method of repressing metastasis of a cancer compromising the administration of a peptide epoxyketone proteasome inhibitor. Furthermore, the method can be performed in combination with the administration of one or more additional therapeutics.

Claims

1. A method for repressing metastasis of a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a peptide epoxyketone proteasome inhibitor or a pharmaceutically acceptable salt thereof, wherein the proteasome inhibitor has a structure of formula (I) or a pharmaceutically acceptable salt thereof

4. The method of claim 1, wherein the cancer is breast cancer.

5. The method of claim 1, wherein the proteasome inhibitor is administered orally.

6. The method of claim 5, further comprising administering one or more additional therapeutic agents.

7. The method of claim 1, wherein the cancer is lung cancer.

2. A method for repressing metastasis of a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a peptide epoxyketone proteasome inhibitor or a pharmaceutically acceptable salt thereof, wherein the peptide epoxyketone has a structure of Formula (II) or a pharmaceutically acceptable salt thereof

3. The method of claim 2, wherein the peptide epoxyketone has the following structure:

8. The method of claim 3, wherein the cancer is breast cancer.

9. The method of claim 3, wherein the cancer is lung cancer.

10. The method of claim 3, wherein the peptide epoxyketone is administered orally.

11. The method of claim 10, wherein the peptide epoxyketone is administered as a tablet.

12. The method of claim 10, wherein the peptide epoxyketone is administered as a capsule.

13. The method of claim 10, wherein the peptide epoxyketone is administered as a pill.

14. The method of claim 8, wherein the peptide epoxyketone is administered orally.

15. The method of claim 14, wherein the peptide epoxyketone is administered as a tablet.

16. The method of claim 14, wherein the peptide epoxyketone is administered as a capsule.

17. The method of claim 14, wherein the peptide epoxyketone is administered as a pill.

18. The method of claim 9, wherein the peptide epoxyketone is administered orally.

19. The method of claim 18, wherein the peptide epoxyketone is administered as a tablet.

20. The method of claim 18, wherein the peptide epoxyketone is administered as a capsule.